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ABSTRACT: The knowledge of in vitro and in vivo stability
of polymeric nanoparticles is vital for the development of
clinical formulations for drug delivery and cell labeling
applications. Förster resonance energy transfer (FRET)-
based fluorescence labeling approaches are promising tools
to study nanoparticle stability under different physiological
conditions. Here, we present the FRET-based stability
assessment of poly(lactic-co-glycolic acid) (PLGA) nano-
particles encapsulating BODIPY-FL12 and Nile Red as the
donor and acceptor, respectively. The stability of PLGA
nanoparticles is studied via monitoring the variations of
fluorescence emission characteristics along with colloidal
characterization. Accordingly, PLGA nanoparticles are colloi-
dally stable for more than 2 weeks when incubated in aqueous buffers in situ, whereas in vitro particle degradation starts in
between 24 and 48 h, reaching a complete loss of FRET at 72 h as shown with fluorescence microscopy imaging and flow
cytometry analysis. PLGA nanoparticles systemically administered to mice predominantly accumulate in the liver, in which
FRET no longer takes place at time points as early as 24 h postadministration as determined by ex vivo organ imaging and flow
cytometry analysis. The results of this study expand our knowledge on drug release and degradation behavior of PLGA
nanoparticles under different physiological conditions, which will prove useful for the rational design of PLGA-based
formulations for various applications that can be translated into clinical practice.
KEYWORDS: FRET, polymeric nanoparticles, PLGA, in vivo stability, drug delivery
1. INTRODUCTION
Drug delivery systems utilizing polymeric nanocarriers have
emerged as versatile tools with tremendous potential in clinical
applications.1−4 Entrapment of drugs within polymeric nano-
particles (NPs) offers the advantages of reduced toxicity and
systemic side effects, as well as improved stability and targeted
delivery of the drug.5 Furthermore, colloidal (e.g., size,
composition, loading efficiency) and functional (e.g., release
profile) properties of nanoparticles can be adjusted to achieve
the desired therapeutic effects.6 An optimally designed drug
delivery system should ensure the availability of the drug at a
specific location for a required period of time.7 Despite recent
advances in the development of drug delivery nanoparticles
with precisely controlled colloidal and functional properties,
their translation to clinical use remains challenging. This is
largely because the nanoparticles developed and tested in vitro
do not necessarily reflect the in vivo performance, especially
when drug release is also dependent on polymer degrada-
tion.8−10 Furthermore, complex biological environments,
including blood components such as serum proteins, lipids,
enzymes, or cells, can interfere with the colloidal and
functional stability of nanoparticles, causing drug leakage or
premature release.11−13 Therefore, the rational design of drug
delivery nanoparticles with an improved therapeutic efficacy
requires the development of robust techniques to monitor the
functional stability of nanoparticles in different physiological
conditions.
Fluorescence labeling strategies are commonly employed to
evaluate drug retention and cellular uptake of nanoparticles.14
Typically, nanoparticles that encapsulate a single type of
fluorescent label are tracked using fluorescence microscopy or
flow cytometry analysis.15 However, the colloidal stability of
nanoparticles cannot be assessed with this approach because
the fluorescence signals originating from the released and
retained dyes cannot be distinguished.16 Alternatively, two-
color labeled nanoparticles can be designed using fluorescent
dyes that exhibit a Förster resonance energy transfer
(FRET).17 FRET is a nonradiative transfer of energy from
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an excited donor molecule (D) to a nearby acceptor (A),
displaying spectral overlap via dipole−dipole coupling.18 The
strong dependence of FRET on the D−A separation distance
can provide useful information on the release13 and
degradation19 profile of nanoparticles encapsulating D−A
dyes. When dyes are in close proximity within the intact
nanoparticle, the energy is transferred from the excited D to A,
resulting in D quenching and A sensitization. Upon dye release
and nanoparticle degradation, the D−A distance becomes too
large for an efficient energy transfer. Therefore, release and
degradation profiles of nanoparticles can be determined by
monitoring the recovery of D emission and loss of A
sensitization using fluorescence spectroscopy and imaging.20,21
FRET-based assessment of dye release and particle
degradation have been reported for various types of polymeric
carriers formulated as self-assembled micelles11,22−24 and
nanoparticles.10,25−28 Among the polymeric carriers, poly-
(lactic-co-glycolic acid) (PLGA) has received particular
attention due to its excellent biocompatibility, tunable
degradation characteristics, and long clinical history.29 Drug
delivery systems based on PLGA particles are already available
on the market (e.g., Lupron Depot by Abbott Laboratories,
USA, and Trelstar by Watson Pharmaceuticals, USA), and new
formulations are under continuous development for various
applications. Although the development of PLGA particles of
varying size,30,31 surface functionality,32−34 and encapsulated
cargo35−37 have been shown in several studies, reports on the
colloidal and functional stability of these particles in vivo are
scarce.38 We have previously shown that PLGA nanoparticles
of ∼200 nm diameter are suitable for cell loading, do not affect
cell viability, and can specifically deliver their cargo to desired
cell populations39−42 with a relatively higher intracellular
uptake compared to micron-sized particles.43
In this study, we present a detailed stability assessment of
PLGA nanoparticles of ∼200 nm diameter in situ, in vitro, and
in vivo, exploiting a FRET-based fluorescence labeling
approach. We study both the functional (i.e., release profile)
and colloidal stability (i.e., degradation) of the PLGA
nanoparticles using FRET. PLGA nanoparticles were loaded
with BODIPY-FL and Nile Red dyes that acted as D and A,
respectively. After optimization of the dye loading ratio, we
studied the dye release and particle degradation profile in
different buffers in situ. In vitro assessment of particle uptake
and stability was done using human-derived peripheral blood
mononuclear cells and mouse-derived bone marrow dendritic
cells. Finally, we tracked nanoparticles systemically adminis-
tered to mouse by extracting and analyzing organs for the
evaluation of in vivo particle stability. Monitoring the recovery
of quenched D fluorescence upon dye release and particle
degradation revealed striking differences under different
physiological conditions. The results demonstrated here will
prove useful for rational design of PLGA nanoparticles for
applications, such as drug delivery or cell loading for therapy
monitoring with an improved therapeutic efficacy.
2. MATERIALS AND METHODS
2.1. Materials. PLGA (Resomer RG 502H), with a 50:50 ratio of
lactic acid−glycolic acid and MW 7000−17 000 Da, was obtained
from Evonik Nutrition & Care GmbH (Germany). Poly(vinyl
alcohol) (PVA, 9000−10 000 Mw, 80%, hydrolyzed) and Nile Red
were obtained from Sigma-Aldrich (USA). CholEsteryl BODIPY-FL
C12 was purchased from Thermo Fisher Scientific (USA) and
acetonitrile was from VWR (The Netherlands). Ultrapure Milli-Q
water (18.2 MΩ cm) was used where necessary (Merck, USA).
RPMI-1640 medium, Anti-Anti (AA), and ß-mercaptoethanol were
obtained from Gibco. X-Vivo medium and ultraglutamine were from
Lonza. Fetal bovine serum (FBS) was purchased from Hyclone (GE
Healthcare, USA).
2.2. Nanoparticle Formulation. Dye-loaded PLGA nano-
particles were prepared via a nanoprecipitation method. Briefly, the
organic phase containing 4 mg of PLGA in 72 μL of acetonitrile was
mixed with the appropriate amounts of fluorescent dyes followed by
dropwise addition to 1 mL of 2% aqueous PVA solution under
constant stirring at 450 rpm. Particles were washed three times with
ultrapure water by centrifugation at 15 000 rpm for 35 min after
evaporation of the organic solvent overnight at 4 °C. Finally, particles
were lyophilized. For the determination of optimal dye concentration
without inducing dye quenching, BODIPY-FL green was loaded
within PLGA nanoparticles at concentrations of 0.1, 0.5, 1.0, 1.3, 1.5,
1.6, and 2.0% (w/w). For the Nile Red encapsulation, the dye
concentration was varied as 0.1, 0.3, 0.7, 1.0, and 1.3% (w/w). Dye
loading ratios determined in the previous optimization steps were
used for coencapsulation of donor (1.0%) and acceptor (0.2%) dyes
to prepare PLGA nanoparticles that exhibit FRET.
2.3. Colloidal and Optical Characterization of Nano-
particles. The size distribution of nanoparticles was measured via
dynamic light scattering (DLS) (Nanotrac Flex, Microtrac). Briefly,
50 μL of the particle suspension was diluted to 1 mL using filtered
Milli-Q water to avoid multiple scattering events. The measurements
were obtained at room temperature (25 °C ± 1 °C), at which the
corresponding water viscosity and refractive index were 0.872 and
1.330 cP, respectively. An average of three measurements was used to
report the Z-average values for each sample. The ζ potential of
nanoparticles was measured using a Zetasizer Nano ZS (Malvern
Instruments). Particles were dispersed in 5 mM NaCl solution for the
measurements, and an average of three measurements was used to
report the ζ potential. Atomic force microscopy (AFM) images of
nanoparticles were obtained with a Catalyst BioScope (Bruker)
coupled to a confocal microscope (TCS SP5II, Leica). 100 μL of the
particle suspension was dried on clean glass substrates, and particles
were imaged in peak-force tapping mode using silicon nitride
cantilevers with nominal spring constants of 0.4 N/m (Bruker).
AFM images were analyzed using NanoScope analysis software
(Bruker).
Optical characterization of fluorescent nanoparticles was done by
measuring the steady-state fluorescence of diluted samples (1 mg/
mL) using Eppendorf semimicro Vis Cuvettes on an LS 55
Fluorescence spectrometer (PerkinElmer). A xenon lamp was used
as the excitation source. Samples were excited at 488 nm, and the
emission was recorded between 500 and 800 nm. The width of
excitation and detection slits and other data collection parameters
were kept the same for each measurement.
2.4. Stability Assessment of PLGA Nanoparticles in Situ.
PLGA nanoparticles encapsulating D and A dyes (will be referred to
as “FRET NP”) were studied in situ to determine dye release and
particle integrity. A suspension of FRET NP in Milli-Q water was
incubated at 37 °C for a period of 2 weeks. Emission spectra and size
distribution of particles were measured at different time points. PLGA
nanoparticles encapsulating the only donor BODIPY-FL green dye
(will be referred to as “green NP”) and acceptor Nile Red dye (will be
referred to as “red NP”) were studied in parallel as a control. The
recovery of FRET-quenched D emission was monitored using
fluorescence spectroscopy and was compared to variations of the
green NP emission; thus, the influence of direct Nile Red excitation
was excluded from the analysis. This process was repeated for
nanoparticles incubated in PBS buffers at pH 7.4 and at pH 5.8 for a
period of 1 week.
2.5. Cell Culture. Peripheral blood mononuclear cells (PBMCs)
were isolated from buffy coats of healthy individuals after informed
consent, using ficoll density centrifugation (Lymphoprep, STEM-
CELL Technologies, Vancouver, Canada). Adherent monocytes were
cultured in X-VIVO 15 media supplemented with 2% human serum
and in the presence of interleukin-4 (300 U/mL) and granulocyte-
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monocyte colony stimulating factor (GM-CSF, 450 U/mL) to obtain
immature dendritic cells (DCs).
Bone marrow-derived DCs (BMDCs) were isolated from the femur
and tibia of donor mice. Isolated cells were then cultured in RPMI-
1640 medium (supplemented with 10% FBS, 1% AA, 1% Ultraglut-
amine, and β-mercaptoethanol) in the presence of murine GM-CSF
(20 ng/mL).
2.6. Cell Labeling. Uptake and intracellular trafficking of
nanoparticles were studied on a monocyte-derived DC (moDC)
culture. Day-3 immature moDCs were collected from the Costar
flasks and counted using Trypan Blue. The cell suspension was diluted
to the desired concentration (0.1 × 106/mL). Then, 0.2 × 105 cells
were plated on sterile coverslips in 24-well plates and were labeled
with green NP at a concentration 1 mg of nanoparticles per million
cells. The cells were then incubated for 6 and 24 h at 37 °C. At each
time point, the medium was removed and the coverslips were washed
carefully with PBS. The cells were then fixed by adding 300 μL of 2%
paraformaldehyde (PFA) and permeabilized with PBA + 0.1%
Saponin. LAMP1 (Sigma-Aldrich)- or EEA1 (BD Bioscience)-specific
primary antibodies (Ab) were incubated with cells followed by
staining with isotype-specific 568AlexaFluor-conjugated secondary
Ab. The cell nuclei were stained with DAPI using 4 μL droplets of a
Mowiol−DAPI mixture. Coverslips were transferred to the slides, kept
overnight in the dark, and then examined with an Olympus FV1000
confocal laser scanning microscope. An argon laser (488 nm) was
used as the excitation source, and images were collected with an
UPLSAPO 60× objective at a 502−538 nm range. Images were then
processed with ImageJ software.
2.7. Stability Assessment of PLGA NP in Vitro. Day-3 human
moDCs and day-14 murine CD103+ BMDCs were labeled with the
particles at a concentration of 1 mg of nanoparticles per million cells
and were incubated for different time points (0.5, 1, 3, 6, 48, and/or
72 h). At each time point, the cells were analyzed with flow cytometry
(BD FACS Verse, BD Biosciences). FlowJo analysis software was used
to determine the mean fluorescence intensity of cells. BMDCs were
also imaged with a Leica DMI6000 epi-fluorescence microscope
equipped with a 63× 1.4 NA oil immersion objective, a metal halide
EL6000 lamp for excitation, a DFC365FX CCD camera, and GFP
filter sets (all from Leica) to measure the variations of intracellular
intensity at the green emission channel for green NP and FRET NP at
24 and 72 h of incubation.
2.8. Stability Assessment of PLGA NP in Vivo. Albino C57BL/
6J female mice (B6 (Cg)-Tyrc-2J) were obtained from Jax Laboratory
and maintained under specific pathogen-free conditions at the Central
Animal Laboratory in Nijmegen, The Netherlands. Experiments were
performed according to the guidelines for animal care of the
Nijmegen Animal Experiments Committee (DEC 2016-0045). Mice
were injected intravenously (i.v.) with 200 μL of either FRET NP or
green NP at a concentration of 10 mg/mL. The organs (liver, spleen,
kidneys, lungs) were isolated at 2 and 24 h postinjection after
sacrificing the mice and were imaged with an IVIS LUMINA in vivo
imaging system with the excitation set to 465 nm, and the emission
was detected at GFP channel (5 s exposure time). Finally, the cells
isolated from the liver were analyzed with flow cytometry.
3. RESULTS AND DISCUSSION
3.1. Formulation and Characterization of Dye-
Loaded PLGA Nanoparticles. PLGA nanoparticles (PLGA
NPs) encapsulating fluorescent dyes were prepared via a
nanoprecipitation method.6 A water-miscible organic solvent
(acetonitrile) containing PLGA and fluorescent dyes was
mixed with the aqueous phase containing 2% PVA solution
under constant stirring. The hydrophobic nature of both dyes
allowed for their encapsulation within PLGA NPs during the
particle formation. PLGA NPs encapsulating only donor
(green nanoparticles), only acceptor (red nanoparticles), and
a combination of donor/acceptor dyes (FRET nanoparticles)
were prepared (Figure 1A). Particles with an average diameter
of ∼200 nm (PDI < 0.2) and a slightly negative ζ potential
(−2.74 ± 0.377 mV for FRET nanoparticles) were obtained
using this preparation method. A representative atomic force
microscopy image of FRET nanoparticles is shown in Figure
1B. BODIPY-FL and Nile Red were selected as the D−A pair,
respectively, due to their excellent spectral overlap44 (Figure
1C).
The large spectral overlap integral, determined as J = 2.25 ×
1015 nm4 M−1 cm−1, ensured an efficient energy transfer
between the BODIPY-FL and Nile Red. The D−A separation
distance, at which the FRET efficiency is 50% (i.e., the Förster
distance, R0) was calculated using eq 1.
κ= Φ −R n J0.02108( )0 2 D 4 1/6 (1)
The FRET orientation factor κ2 = 2/3, the refractive index of
PLGA n = 1.46, and the BODIPY-FL quantum yield ΦD = 0.9
led to a Förster distance of R0 = 5.5 nm. Therefore, an efficient
Figure 1. (A) Schematic illustration for the preparation of PLGA NPs encapsulating only donor (green NPs), only acceptor (red NPs), and
coencapsulating donor and acceptor dyes (FRET NPs). (B) A representative atomic force microscopy height image of FRET NPs coencapsulating
1% donor and 0.2% acceptor (w/w) dyes. Scan size: 750 nm × 750 nm. Scale bar: Z-axis. (C) Normalized excitation (dashed curves) and emission
(solid curves) spectra of BODIPY-FL (green) and Nile Red (red) donor−acceptor pair.
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FRET distance of approximately 2.75−11 nm that corre-
sponded to ca. 0.5 to 2-fold R0 was obtained using this FRET
pair.
An ideal FRET probe to assess particle stability should be
robust and efficient, which largely depends on the photo-
physical properties of the fluorescent dyes used as FRET pairs.
The robustness ensures that observed changes in the emission
characteristics are solely due to dye release and particle
degradation rather than modified emission properties of
fluorescent dyes due to, e.g., temperature. In this respect,
BODIPY dyes with an excellent stability are good candidates to
be utilized as FRET probes. However, previously reported
FRET pairs constructed with BODIPY dyes as both donors
and acceptors displayed smaller Förster distances.20 The
Förster distance is a measure of the donor−acceptor separation
distances that can be probed efficiently using FRET. The
ability to detect FRET at larger molecular separation distances
results in improved precision even at larger length scales. By
pairing the BODIPY donor with a Nile Red acceptor, we
drastically improved the Förster distance as 5.5 nm, which
enabled an efficient energy transfer between donor and
acceptor molecules at separation distances as large as 11 nm
(2-fold of Förster distance). Therefore, compared to previously
reported studies, the FRET system we developed displayed
both a high robustness and a more efficient energy transfer at
larger distances.
Prior to preparation of FRET NPs, loading ratios of both
dyes were optimized. A series of dye concentrations in the
0.1−2.0% (w/w) range were used for encapsulation within
PLGA NPs. Self-quenching of dyes was observed at
concentrations above 1.3% and 0.3% (w/w) for the donor
(Figure 2A) and acceptor dyes (Figure 2B), respectively.
Therefore, loading ratios of 1.3% D and 0.3% A were used for
coencapsulation to prepare FRET NPs, for which an efficient
quenching of D emission was observed. Lowering the dye
fractions to 1.0% D and 0.2% A was observed to increase the
efficiency of D quenching further. Figure 2C shows the
emission spectra of FRET NPs with different D−A fractions
normalized at the acceptor emission wavelength (∼615 nm).
The size distribution analysis of FRET NPs showed a mean
Figure 2. (A) Fluorescence intensity of green NPs prepared with various concentrations of BODIPY-FL (from 0.1% to 2.0%). (B) Fluorescence
intensity of red NPs prepared with various concentrations of Nile Red (from 0.1% to 1.3%). (C) Emission spectra of FRET NPs loaded with 1.0%
D−0.2% A (black), 1.0% D−0.3% A (red), and 1.3% D−0.3% A (blue) normalized at the acceptor emission wavelength (λexcitation 488 nm). (D)
Size distribution of FRET NPs with the depicted D−A loading ratios. (E) Emission spectra of green NPs loaded with 1.0% BODIPY-FL (green),
red NPs loaded with 0.2% Nile Red (red), and FRET NPs coencapsulating 1.0% BODIPY-FL and 0.2% Nile Red (orange). (F) Emission spectra of
intact FRET NPs dispersed in water (orange) and disassembled FRET NPs dispersed in acetonitrile (green).
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diameter of ∼200 nm with a small PDI (<0.2) for all particles
(Figure 2D). Other tested loading ratios displayed either a low
FRET efficiency (Figure S1A) or larger average particle size
(Figure S1B). Therefore, the formulation containing 1.0% D
and 0.2% A was selected for further studies. For this loading
ratio, the FRET efficiency (E) was calculated as ∼70% using eq
2.
= −E I
I
1 DA
D (2)
IDA and ID are the total donor fluorescence intensities in the
presence and absence of the acceptor, respectively.
Steady-state fluorescence spectroscopy analysis revealed
quenching of D emission accompanied by a sensitized A
emission for FRET NPs compared to the emission spectra of
green NPs containing only 1.0% BODIPY-FL and red NPs
containing only 0.2% of Nile Red (Figure 2E). Disassembly of
FRET NPs upon resuspension in acetonitrile resulted in the
recovery of D emission and loss of A sensitization (Figure 2F),
indicating the relevance of emission characteristics to structural
integrity. Relying on these observations, the spectral changes of
FRET NPs were monitored under different physiological
conditions to obtain information on the structural changes of
NPs that result in an increase in the D−A separation distance,
such as dye release and particle degradation.
3.2. Assessment of Dye Release and Particle Stability
in Situ. The optical and colloidal analysis of FRET NPs
incubated in an aqueous solution at 37 °C enabled the particle
stability assessment in situ. Fluorescence emission spectra and
size distribution of NPs were measured at different time points
up to 2 weeks. Figure 3A shows the emission spectra of FRET
NPs normalized at the emission peak of the acceptor dye. A
gradual recovery of D emission was observed at longer
incubation times, which indicated a lower FRET efficiency at
these time points. The FRET ratios were calculated by dividing
the emission intensity of A by the emission intensity of D at
each measurement point (Figure 3B). As a control, green NPs
containing only 1.0% D were studied in parallel. Calculation of
FRET ratios is a useful way to analyze FRET as it involves the
contribution of both D and A emission intensities simulta-
neously. A decrease in FRET ratio would indicate a less
efficient energy transfer between the D/A pair due to dye
release or particle degradation. Indeed, a sharp decrease of
FRET ratio was observed at day 1, which was due to an initial
burst release of dyes. The biphasic release pattern that involves
this initial burst followed by a more sustained release is
typically observed for PLGA NPs.45 The gradual decrease of
FRET ratio at the following time points corresponded to the
sustained release phase.
Monitoring the green NPs in parallel ensured that the
observed changes in the FRET ratio were not due to the
influence of other factors (such as temperature) on the
photophysical properties of the BODIPY-FL. As shown in
Figure 3B, the variations in the FRET ratio values of green NPs
were negligible compared to FRET NPs due to the remarkable
stability of BODIPY dyes.46
Here, the decrease of FRET efficiency was mainly the result
of dye release, particle degradation, or a combination of both.
A nearly complete degradation of PLGA NPs with an average
size of 230 nm was previously reported to take place within 10
weeks of incubation.47 Interestingly, these nanoparticles
maintained their size until they were totally degraded, despite
the decrease in their molecular weight. In our study, the
particle size measurements showed that the average size of
nanoparticles remained within the 200 nm range during the
incubation period as well (Figure 3C). Although a certain
degree of particle degradation possibly took place during the 2
weeks of incubation,48 it can be concluded that dye release was
the major mechanism that resulted in a decreased FRET
efficiency.
On the last day of incubation, FRET NPs were redispersed
in acetonitrile in order to induce particle disassembly. These
“broken” FRET NPs served as “no-FRET controls”. The
emission spectra of FRET NPs dispersed in water and
acetonitrile in comparison to green NPs are shown in Figure
3D. The comparison of the emission spectra of FRET NPs to
their “broken” counterparts on day 14 revealed the presence of
FRET still on week two, which was evident by the A
sensitization peak for the FRET NPs dispersed in water. The
small shoulder observed around 620 nm for the “broken”
FRET particles was due to the direct excitation of acceptor
dye.
The release profile of FRET NPs was also studied in neutral
and slightly acidic conditions as pH can influence cargo release
mechanisms and particle degradation characteristics.49 FRET
NPs dispersed in PBS buffer with pH 5.8 (Figure 4A,B) or pH
7.4 (Figure 4C,D) were incubated at 37 °C for a period of 7
days. Fluorescence emission spectra and particle size
distribution (Figure S2) were recorded at different time
points. While a higher initial burst release was observed at pH
7.4 (Figure 4D), the release was faster at pH 5.8 in the
following release period (Figure 4B). The burst release takes
place during the initial water uptake and swelling of the
lyophilized nanoparticles. The PLGA used for the preparation
of nanoparticles was terminated with carboxylic acid groups.
Figure 3. Stability assessment of PLGA NPs in situ. (A) Fluorescence
emission spectra of FRET NPs normalized at the acceptor emission
peak measured at 4 h (black), day 1 (red), day 2 (blue), day 3
(magenta), day 6 (green), day 8 (navy), and day 14 (purple).
Excitation wavelength: 488 nm. (B) FRET ratio plot for FRET NPs
(orange) and green NPs (green) at different measurement time
points. (C) Average particle size of FRET NPs measured at different
incubation times. (D) Normalized emission spectra of FRET NPs
(black), green NPs (blue), and disassembled FRET NPs (red) on day
14.
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Therefore, it is very likely that a higher degree of interactions
took place between the cationic species present in the buffer
and the carboxylic acid groups on the polymer, which resulted
in the facilitated diffusion and a higher burst release of dyes at
pH 7.4. A higher burst release at pH 7.4 compared to more
acidic conditions was reported for PLGA NPs also in previous
studies.45
In addition to burst release, the pH has been shown to
influence the degradation mechanism of PLGA NPs as well.50
However, an incubation period of 7 days is probably too short
to observe the influence of polymer degradation on the release
profile at different pH values. In one of our previous studies,
we also have shown that the release of a hydrophobic dye was
faster in a more acidic environment.39 Thus, in situ release
behavior of the formulations that we reported previously is in
good agreement with the results presented in this work.
3.3. Assessment of Cellular Uptake and Particle
Stability in Vitro. The intracellular fate of nanoparticles has
a strong influence on their therapeutic efficacy particularly
when the encapsulated cargo is unstable at specific intracellular
locations due to, e.g., organelle’s pH.51 Therefore, it is
necessary to study the cellular uptake, intracellular trafficking,
and in vitro stability of polymeric drug delivery nanoparticles.
Monocyte-derived DCs (moDCs) obtained from healthy
donors, known to have a high phagocytic capacity, were used
for the analysis of uptake and intracellular trafficking of NPs.
Green NPs containing only 1.0% D were used to examine the
intracellular trafficking. MoDCs incubated with green NPs
were fixed at 6 and 24 h of incubation for confocal microscopy
(Figure 5A). In order to monitor the colocalization of
nanoparticles with early endosomes and lysosomes, EEA1
and LAMP1 staining were performed, respectively. The
intracellular BODIPY-FL signal was observed to increase at
24 h compared to 6 h of incubation. In addition, while the NPs
colocalized with the early endosomes at 6 h, only a partial
Figure 4. Normalized fluorescence emission spectra of FRET NPs
incubated at pH 5.8 (A) and pH 7.4 (C) at 0.5 h (black), 4 h (red),
day 1 (blue), day 3 (magenta), and day 7 (green). Excitation
wavelength: 488 nm. FRET ratio plot for FRET NPs (orange) and
green NPs (green) dispersed in PBS buffer with pH 5.8 (B) and pH
7.4 (D).
Figure 5. (A) Confocal microscopy images of moDCs incubated with green NPs for 6 and 24 h. Cells were stained with DAPI for nuclei (blue) and
either with EEA1 for early endosomes or with LAMP1 for lysosomes (red). The fluorescence emission of green NPs is presented in green. The
overlap between green NPs and EEA1 or LAMP1 is shown in yellow. (B) Mean fluorescence intensity values obtained with flow cytometry at 4 and
24 h for moDCs incubated at 4 °C (light gray) and 37 °C (dark gray) with green NPs. (C) Mean fluorescence intensity plot for moDCs incubated
with green NPs (green) and FRET NPs (orange) for various time points up to 48 h.
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overlap with the early endosomes and lysosomes was observed
at 24 h. This is in accordance with the capability of PLGA
nanoparticles to escape endolysosomal pathways as has been
shown also in previous studies.43,52,53 The mechanism behind
the nanoparticle escape is likely due to reversal of the surface
charge of nanoparticles from anionic to cationic in acidic
endolysosomal pH. This reversal leads to the interaction of
nanoparticles with endolysosomal membrane and escape to
cytosol.53 Thus, the fact that we observe only partial
colocalization with an endolysosomal compartment could be
explained by this escape mechanism.
In order to evaluate the energy dependence of NP uptake,
cells were incubated with green NPs at 4 °C and mean
fluorescence intensities were measured at 4 and 24 h using flow
cytometry. The intracellular BODIPY-FL signal was negligible
at 4 °C compared to 37 °C at both incubation times (Figure
5B), which demonstrated that NPs were mainly taken up via
energy-dependent endocytic pathways. The low level of
intracellular fluorescence at 4 °C can be attributed to the
passive entry of leaked dye molecules via diffusion39 or
adsorption of nanoparticles to the cell surface.54 Dye leakage is
indeed a common problem for polymeric nanoparticles, which
can result in misinterpretation of their cellular uptake and
intracellular distribution.16
Cellular uptake and in vitro stability of nanoparticles was
evaluated by flow cytometry analysis of moDCs incubated with
green NPs and FRET NPs for a period of 48 h (Figure 5C).
The intracellular fluorescence intensity increased rapidly up to
ca. 6 h, and then reached a plateau at 24 h for both particle
types. A slight decrease of the mean fluorescence intensity was
observed for green NPs at 48 h, which can be an indication of
dye release as free dyes show lower emission intensities in an
aqueous environment than in the NPs.20 Nevertheless, the
emission intensity difference between green NPs and FRET
NPs revealed the presence of FRET still at 48 h.
In vitro particle stability assessment was also performed on
murine CD103+ BMDCs. Cells incubated with FRET NPs and
green NPs were analyzed with fluorescence microscopy
imaging and flow cytometry at 24 and 72 h of incubation
(Figure 6). Fluorescence microscopy images were obtained
using excitation and emission filters suitable for the detection
of BODIPY-FL. An efficient donor quenching was observed at
24 h of incubation as indicated by the dimmer intracellular
fluorescence intensity for FRET NPs compared to green NPs
(Figure 6A). On the other hand, similar intracellular intensities
of donor emission observed at 72 h revealed that there was no
longer an efficient energy transfer at this time point between
donor and acceptor dyes. These findings were confirmed by
the flow cytometry analysis as well (Figure 6B). The mean
fluorescence intensity values of FRET NPs measured at the
green emission channel was comparable to that of green NPs at
72 h, which confirmed the recovery of donor emission at this
time of incubation.
Overall, fluorescence microscopy imaging and flow cytom-
etry analyses revealed a significantly faster donor recovery in
vitro, reaching a complete loss of FRET at 72 h probably due
to both dye release and particle degradation. It should be
noted that cell culture media can alter the colloidal and
chemical properties of NPs due to the presence of proteins and
high ion content.55 Furthermore, during their uptake through
the endocytic pathway, nanoparticles are exposed to varying
physiological conditions such as acidic pH of late endosomes55
and high levels of hydrolytic enzymes in lysosomes.56 All of
these factors affect nanoparticle stability and degradation,
resulting in a faster release of the encapsulated cargo in vitro
when compared to in situ settings.
3.4. Assessment of Particle Stability in Vivo. In vivo
stability of particles systemically administered to mice was
studied via ex vivo organ imaging and flow cytometry (Figure
7). Green NPs and FRET NPs were injected intravenously
(i.v.) for liver imaging, and cells were isolated at 2 and 24 h
after injection. In accordance with the biodistribution studies
reported for PLGA NPs after i.v. administration,8,57,58 NPs
were detected mainly in liver as confirmed by flow cytometry
analysis and ex vivo organ imaging (Figure S3). Therefore,
cells isolated from the liver were used in the further analyses. A
higher fluorescence emission intensity was detected in the liver
of mice injected with green NPs (Figure 7A) compared to
those injected with FRET NPs (Figure 7B). For both
experimental groups, a significant decrease of fluorescence
emission was observed at the 24 h time point. The decrease in
emission probably resulted from the particle degradation or
Figure 6. (A) Fluorescence microscopy images of murine BMDCs incubated with FRET NPs and green NPs for 24 and 72 h collected at the green
emission channel. Cell nuclei are stained with DAPI (blue). (B) Mean fluorescence intensity value BMDCs incubated with green NPs (light gray)
and FRET NPs (dark gray) measured at the green emission channel using flow cytometry. A complete recovery of donor quenching is observed at
72 h.
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enhanced release, accompanied by fast clearance of the dyes
from the liver. A similar observation was also reported by
Simon et al., who showed a significant decrease of nanoparticle
concentration in various tissues over 24 h period.57 Therefore,
the observed decrease in emission could be also attributed to a
rapid clearance of the nanoparticles from the liver as well.
Next, we isolated the cells from this organ and analyzed
them with flow cytometry. FRET was still detectable at 2 h
after administration as depicted by a lower mean fluorescence
intensity at the donor emission channel compared to the cells
obtained from the liver of a mouse injected with green NPs
(Figure 7C). On the other hand, a reduced mean fluorescence
intensity was observed for the cells isolated at the 24 h time
point for both FRET NPs and green NPs (Figure 7C).
Furthermore, intensity peaks for both conditions showed an
overlap, indicating the loss of FRET at this time point.
Additional analysis of the cells shown in Figure 7C revealed an
almost complete loss of FRET in vivo within 24 h after
injection (Figure S4).
A previous study by Mohammad et al. showed degradation
of PLGA nanoparticles with a slight reduction in molecular
weight already within the first 24 h after i.v. administration and
predominant accumulation in the liver.8 In that study, the
degradation profile of 200 nm PLGA nanoparticles showed
differences between in vitro and in vivo conditions, as well as
between various types of tissues. In our study, a faster recovery
of the donor emission was observed in vivo. However, here we
used a lower molecular weight polymer (7000−17 000 Da),
which can lead to faster polymer degradation and a more rapid
drug release.59 The impact of enzymes on the PLGA
degradation is unclear; nevertheless, due to the fact that liver
has a high concentration of esterases,8 we cannot exclude a
possible influence of these enzymes on the faster release and
degradation observed in our study. The presence of proteins in
blood and variations of pH in different tissue types could also
affect the degradation profile of the nanoparticles. Therefore,
our in vivo study suggests the involvement of additional
parameters, e.g., enzymes, on release and nanoparticle
degradation.
4. CONCLUSION
It is of major importance to monitor the stability of polymeric
nanoparticles under different physiological conditions for the
development of clinically applicable formulations. In this study,
we demonstrated that FRET is a powerful tool to assess the
stability of PLGA nanoparticles by encapsulating BODIPY-FL
green and Nile Red dyes as the donor−acceptor pair,
respectively. These FRET NPs of ∼200 nm in size showed
∼70% FRET efficiency. Optical and colloidal analysis of
nanoparticles revealed that PLGA nanoparticles were stable for
at least 2 weeks in situ, while in vitro particle degradation
started in between 24 and 48 h, reaching a complete recovery
of donor emission at 72 h. The nanoparticles were readily
taken up by human-derived moDCs mainly via energy-
dependent endocytic pathways, but could escape the
endolysosomal routes after uptake. In vivo studies showed
the accumulation of systemically administered PLGA nano-
particles in the liver and particle degradation within 24 h. The
results of our study will have a major impact on research
focusing on the applications such as drug delivery and cell
therapy monitoring using PLGA nanoparticles, as they provide
a better understanding of the degradation processes and an
Figure 7. Ex vivo imaging of the liver 2 and 24 h after i.v. injection of (A) Green NPs and (B) FRET NPs. (Excitation wavelength = 465 nm,
emission filter = GFP, exposure time = 5 s.) (C) Flow cytometry histograms of cells isolated from the liver at 2 and 24 h postinjection. (Excitation
wavelength = 488 nm, detection filter = FITC). Red: unlabeled control. Green: Green NPs. Orange: FRET NPs.
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attractive way to monitor the uptake of the nanoparticles and
release of encapsulated cargo.
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